JP2024540417A5 - - Google Patents
Info
- Publication number
- JP2024540417A5 JP2024540417A5 JP2024527216A JP2024527216A JP2024540417A5 JP 2024540417 A5 JP2024540417 A5 JP 2024540417A5 JP 2024527216 A JP2024527216 A JP 2024527216A JP 2024527216 A JP2024527216 A JP 2024527216A JP 2024540417 A5 JP2024540417 A5 JP 2024540417A5
- Authority
- JP
- Japan
- Prior art keywords
- atezolizumab
- administered
- lurubinectedin
- treatment
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21383013 | 2021-11-08 | ||
| EP21383013.6 | 2021-11-08 | ||
| PCT/EP2022/081155 WO2023079177A1 (en) | 2021-11-08 | 2022-11-08 | Lurbinectedin and atezolizumab combinations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024540417A JP2024540417A (ja) | 2024-10-31 |
| JP2024540417A5 true JP2024540417A5 (enExample) | 2025-11-18 |
Family
ID=78820304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024527216A Pending JP2024540417A (ja) | 2021-11-08 | 2022-11-08 | ルルビネクテジン及びアテゾリズマブの組合せ |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240415834A1 (enExample) |
| EP (1) | EP4430075A1 (enExample) |
| JP (1) | JP2024540417A (enExample) |
| KR (1) | KR20240099455A (enExample) |
| AU (1) | AU2022381992A1 (enExample) |
| CA (1) | CA3237009A1 (enExample) |
| IL (1) | IL312263A (enExample) |
| MX (1) | MX2024005589A (enExample) |
| WO (1) | WO2023079177A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202547489A (zh) * | 2024-04-30 | 2025-12-16 | 西班牙商瑪製藥股份有限公司 | 化合物ia於包括與阿替利珠單抗的組合療法之癌症的治療中之用途 |
| WO2025228594A1 (en) * | 2024-04-30 | 2025-11-06 | Pharma Mar, S.A. | Use of ecubectedin in the treatment of cancers including combination therapy with atezolizumab |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0102232L (sv) | 2001-06-25 | 2003-02-06 | Anoto Ab | Förfarande och anordning i ett digitalt kommunikationssystem |
| GB0119243D0 (en) | 2001-08-07 | 2001-10-03 | Pharma Mar Sa | Antitumoral analogs of ET-743 |
| PE20252386A1 (es) * | 2019-11-21 | 2025-10-10 | Pharma Mar Sa | Metodo de tratamiento del cancer de pulmon de celulas pequenas con formulaciones de lurbinectedina |
-
2022
- 2022-11-08 IL IL312263A patent/IL312263A/en unknown
- 2022-11-08 WO PCT/EP2022/081155 patent/WO2023079177A1/en not_active Ceased
- 2022-11-08 JP JP2024527216A patent/JP2024540417A/ja active Pending
- 2022-11-08 CA CA3237009A patent/CA3237009A1/en active Pending
- 2022-11-08 EP EP22814358.2A patent/EP4430075A1/en active Pending
- 2022-11-08 KR KR1020247019194A patent/KR20240099455A/ko active Pending
- 2022-11-08 AU AU2022381992A patent/AU2022381992A1/en active Pending
- 2022-11-08 MX MX2024005589A patent/MX2024005589A/es unknown
- 2022-11-08 US US18/703,491 patent/US20240415834A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200308286A1 (en) | Methods, compositions, and kits for treatment of cancer | |
| CN113164500A (zh) | 治疗去势抵抗性和去势敏感性前列腺癌的方法 | |
| EP3313433A1 (en) | Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of cancer | |
| JP2015518888A (ja) | 腫瘍疾患を治療するための１７−アルファ−ヒドロキシラーゼ（ｃ１７，２０−リアーゼ）インヒビターと特定のｐｉ−３ｋインヒビターとの組み合わせ | |
| AU2020309837A1 (en) | Administration of sting agonist and checkpoint inhibitors | |
| WO2020249018A1 (zh) | 治疗驱动基因阳性肺癌的联用药物组合物 | |
| JP2024540417A5 (enExample) | ||
| US20240415834A1 (en) | Lurbinectedin and atezolizumab combinations | |
| JP7352582B2 (ja) | Ｓｕｍｏ活性化酵素阻害剤及び抗ｃｄ２０抗体の投与 | |
| JP2024536275A (ja) | がんを治療する方法及びその医薬組成物 | |
| WO2020233602A1 (zh) | 用于联合治疗小细胞肺癌的喹啉衍生物 | |
| CN112043831A (zh) | 用于联合治疗乳腺癌的喹啉类化合物 | |
| WO2022101255A1 (en) | Lurbinectedin and irinotecan combinations | |
| US12419890B2 (en) | Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors | |
| KR20230110254A (ko) | Sting 작용제, 관문 저해제, 및 방사선의 투여 | |
| CN117224689B (zh) | 联合抗her2抗体和化疗剂治疗胃癌的用途 | |
| US20230218618A1 (en) | Administration of sumo-activating enzyme inhibitor and anti-cd38 antibodies | |
| US20240390360A1 (en) | Therapeutic Combinations Of Orally Administered Paclitaxel, A P-gp Inhibitor, And A Checkpoint Inhibitor For The Treatment Of Solid Tumors | |
| WO2025203012A1 (en) | Kras g12c inhibitor for use for the treatment of non-small cell lung cancer | |
| CN116265030A (zh) | 包含酪氨酸激酶抑制剂德立替尼的药物组合 |